Stay updated with breaking news from Tom Graney. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Completed Patient Enrollment for Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for treatment of Diabetic Macular Edema (DME) in treatment naïve subjects US IRB Approval of Protocol Amendment
Completed Patient Enrollment for Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for treatment of Diabetic Macular Edema (DME) in treatment naïve...
Leuven, BELGIUM, Boston, MA, US - January 4, 2022 - 06.00 PM CET - Oxurion NV(Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic
Negma Group has converted 200 convertible bonds in Oxurion resulting in a EUR 500,000 capital increase. This is part of Negma Group's EUR 30 million Capital Commitment1 that will allow Oxurion to focus
Leuven, BE, Boston, MA, US - November 4, 2021 - 07.00 AM CET - OxurionNV(Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies